

Press release 2012-11-23



Letter of Intent signed to enable worldwide marketing and sales of the GEMini™ ED detector panel

C-RAD AB with its three fully owned subsidiaries in Sweden and three international sales companies are all active in the field of radiation therapy. The company has signed a Letter of Intent with Cablon Medical B.V, the Netherlands, for initiating worldwide marketing and sales of its GEMini™ ED detector together with Cablon's clinical software for portal dosimetry and imaging.

The GEMini™ ED is an advanced flat panel detector based on the Gas Electron Multiplier (GEM) technology licensed from CERN, Switzerland. Its many unique features such as dose linearity, dose rate independence and greatly improved radiation hardness makes it the only detector on the market that is fully optimized both for portal imaging and portal dosimetry applications.

At signing of a final agreement and completion of the technical integration, a state-of-the-art solution for pre-treatment imaging, online verification and assessment of the delivered dose at each fraction will be offered to clinicians worldwide.

Erik Hedlund, CEO, C-RAD AB:

"We have for some time been looking for the right partner to bring the GEMini™ ED detector to the market. Together with Cablon's well-proven clinical software, it is now within our reach to provide the very best package available for portal dosimetry and imaging."

For further information:

Erik Hedlund, CEO C-RAD AB, Phone +46-(0)18-66 69 31, E-Mail erik.hedlund@c-rad.se

About C-RAD AB

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries in Sweden; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD has own sales companies in Germany, USA and China. The headquarter of the group is located in Uppsala, Sweden. Numbers of employees are currently 22 people. The activities at C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company's first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD AB is listed at Nasdaq Omx First North Premier. The company's Certified Advisor is Erik Penser Bankaktiebolag.